Brief: Jiangsu Hengrui Pharmaceuticals Signs Licensing Agreement With Glenmark Specialty S.A.
24/09/2025 10:45
Sept 24 (Reuters) - Jiangsu Hengrui Pharmaceuticals Co Ltd 600276.SS: SAYS SIGNS LICENSING AGREEMENT WITH GLENMARK SPECIALTY S.A. FOR PROJECT SHR-A1811 TO RECEIVE DOWN PAYMENT OF $18 MILLION, MILESTONE PAYMENT OF UP TO $1.1 BILLION Source text Further company coverage: 600276.SS (Reporting by Beijing Newsroom) ((Shi.Bu@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter